Acute Neurovascular Syndromes: Hurry Up, Please, It’s Time1

“It isn’t that they can’t see the solution. It is that they can’t see the problem.” 2 Less than 20 years ago, the most common cited reason for the admission of a patient with stroke to hospital was for nursing or general nonmedical care.3 Admission to make or confirm the diagnosis or for medical treatment were mentioned less than half as often. In the same study, the most common reasons for patients remaining in the community were that they had suffered a minor stroke or services were available in the community for assessment and work-up. The evidence surrounding the benefit of aspirin in acute stroke, the reduction of death and dependence with admission of patients to dedicated stroke units, and perhaps most controversially, the demonstration of the efficacy of thrombolysis, by either intravenous or intra-arterial routes, in reducing disability following acute ischemic stroke had yet to appear.4,5 This article does not seek to re-examine the debate surrounding the use of thrombolysis in acute ischemic stroke. This has been explored at length elsewhere.6–8 The aim of this article is to explore the new perspective on the treatment of hyperacute cerebral ischemia that has arisen because of the increasing use of tissue plasminogen activator (tPA), in particular the influence of time. The organization of acute stroke services is now required to be time sensitive to ensure that the maximum number of patients eligible for thrombolysis have the greatest chance of a good neurological outcome as possible.9 As a result, patients are presenting sooner, emergency services are prioritizing the transport of these patients to hospital, and physicians are assessing these patients more quickly.10 However, thrombolysis in acute cerebral ischemia is not a panacea, just as it has not been in acute coronary syndromes. Rather, it has provided a …

[1]  S. Sidney,et al.  Short-term prognosis after emergency department diagnosis of TIA. , 2000, JAMA.

[2]  E. Braunwald,et al.  Unstable angina. A classification. , 1989, Circulation.

[3]  Zheng-Ming Chen,et al.  CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke , 1997, The Lancet.

[4]  R. Higashida,et al.  Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial , 1999 .

[5]  Michael F. Oliver,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. , 2001, Indian heart journal.

[6]  A. Buchan,et al.  The fast assessment of stroke and transient ischemic attack to prevent early recurrence (FASTER) trial , 2003 .

[7]  Richard P. Lewis,et al.  ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). , 1996, Journal of the American College of Cardiology.

[8]  R. Califf,et al.  Acute Coronary Syndromes in the GUSTO-IIb Trial Prognostic Insights and Impact of Recurrent Ischemia , 1998 .

[9]  P. Sandercock,et al.  Why are patients with acute stroke admitted to hospital? , 1986, British medical journal.

[10]  D. Sackett,et al.  Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. , 1991, The New England journal of medicine.

[11]  A. Buchan,et al.  Early risk of stroke after a transient ischemic attack in patients with internal carotid artery disease , 2004, Canadian Medical Association Journal.

[12]  R. Grieve When will enough be enough? , 1993, Nature.

[13]  Romesh Khardori Stereotyping may highlight diagnoses that might be missed , 2001, BMJ : British Medical Journal.

[14]  L. Elveback,et al.  Transient cerebral ischemic attacks in a community. Rochester, Minnesota, 1955 through 1969. , 1973, Mayo Clinic proceedings.

[15]  S. Sidney,et al.  Head Computed Tomography Findings Predict Short-Term Stroke Risk After Transient Ischemic Attack , 2003, Stroke.

[16]  J. Kirkpatrick,et al.  Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. , 1998, Journal of insurance medicine.

[17]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[18]  S. Warach,et al.  Early ischemic lesion recurrence within a week after acute ischemic stroke , 2003, Annals of neurology.

[19]  P. Lyden Further randomized controlled trials of tPA within 3 hours are required-not! , 2001, Stroke.

[20]  P. Akins,et al.  Intra-arterial prourokinase for acute ischemic stroke. , 2000, JAMA.

[21]  M. Verbeek,et al.  Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients , 2003, Brain Research Bulletin.

[22]  Carl J Pepine,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.

[23]  A. Buchan,et al.  Thrombolysis must be considered after stroke , 2001, BMJ : British Medical Journal.

[24]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[25]  L. Myer,et al.  Condom gap in Africa is wider than study suggests , 2001, BMJ : British Medical Journal.

[26]  S. Ellis,et al.  Tissue-plasminogen activator for acute ischaemic stroke , 1997, The Lancet.

[27]  M. Ezekowitz,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. , 2001, JAMA.

[28]  À. Rovira,et al.  C-Reactive Protein Predicts Further Ischemic Events in First-Ever Transient Ischemic Attack or Stroke Patients With Intracranial Large-Artery Occlusive Disease , 2003, Stroke.

[29]  D. Sackett,et al.  Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. , 1998, The New England journal of medicine.

[30]  A. Demchuk,et al.  Why are stroke patients excluded from TPA therapy? , 2001, Neurology.

[31]  R. Lindley,et al.  Further randomized controlled trials of tissue plasminogen activator within 3 hours are required. , 2001, Stroke.

[32]  Peter Sandercock,et al.  The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997, The Lancet.

[33]  A. Buchan,et al.  Organization of regional and local stroke resources: Methods to expedite acute management of stroke , 2004, Current neurology and neuroscience reports.

[34]  ZhengMingChen,et al.  Indications for Early Aspirin Use in Acute Ischemic Stroke , 2000 .

[35]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[36]  P. Sandercock,et al.  Very Early Risk of Stroke After a First Transient Ischemic Attack , 2003, Stroke.

[37]  M. Eliasziw,et al.  Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis , 2003, The Lancet.

[38]  C Warlow,et al.  Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. , 2000, Stroke.